Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment

Authors
Publication date
Publisher
'Ovid Technologies (Wolters Kluwer Health)'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Crossref

      redirect
      oaiinfo:doi/10.1097%2Fmeg.0b013e3...
      Last time updated on 05/06/2019